【Kangpu Biotech Inc.】2026 Q1 EPS -0.07 NTD
Key facts
- 【Kangpu Biotech Inc.】2026 Q1 EPS -0.07 NTD
- Kangpu Biotech Inc. announced its Q1 2026 financial results, reporting an EPS of -0.07 NTD, with zero revenue and a net loss of 108 million NTD. This indicates a loss-making quarter for the biotechnology company.
- Source: PR Times
- Date: March 1, 2026
Direct answer
Kangpu Biotech Inc. announced its Q1 2026 financial results, reporting an EPS of -0.07 NTD, with zero revenue and a net loss of 108 million NTD. This indicates a loss-making quarter for the biotechnology company.
- Citation
- 【Kangpu Biotech Inc.】2026 Q1 EPS -0.07 NTD (March 1, 2026), PR Times
- Source
- PR Times
- Date
- March 1, 2026
Kangpu Biotech Inc. announced its Q1 2026 financial results, reporting an EPS of -0.07 NTD, with zero revenue and a net loss of 108 million NTD. This indicates a loss-making quarter for the biotechnology company.
📋 Article Processing Timeline
- 📰 Published: March 1, 2026 at 09:00
- 🔍 Collected: May 1, 2026 at 08:00 (1463h 0m after Published)
- 🤖 AI Analyzed: May 1, 2026 at 08:56 (56 min after Collected)
Company Code: 6919
Company Name: Kangpu Biotech Inc.
Industry: Biotechnology and Medical
Year/Quarter: 2026 Q1
Basic Earnings Per Share: -0.07 NTD
Operating Revenue: 0 NTD
Net Profit After Tax: -108 million NTD
Keywords: Financial Report, Biotechnology and Medical, EPS
Company Name: Kangpu Biotech Inc.
Industry: Biotechnology and Medical
Year/Quarter: 2026 Q1
Basic Earnings Per Share: -0.07 NTD
Operating Revenue: 0 NTD
Net Profit After Tax: -108 million NTD
Keywords: Financial Report, Biotechnology and Medical, EPS
FAQ
What are the key facts in this article?
Kangpu Biotech Inc. announced its Q1 2026 financial results, reporting an EPS of -0.07 NTD, with zero revenue and a net loss of 108 million NTD. This indicates a loss-making quarter for the biotechnology company.
What is the direct answer?
Kangpu Biotech Inc. announced its Q1 2026 financial results, reporting an EPS of -0.07 NTD, with zero revenue and a net loss of 108 million NTD. This indicates a loss-making quarter for the biotechnology company.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-6919-2026Q1 | March 1, 2026